Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction by Stingl, L et al.
Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800,
radiosensitise tumour cells through cell-cycle impairment,
increased DNA damage and repair protraction
L Stingl
1, T Stu ¨hmer
2, M Chatterjee
2, MR Jensen
3, M Flentje
1 and CS Djuzenova*,1
1Klinik fu ¨r Strahlentherapie der Universita ¨t Wu ¨rzburg, Josef-Schneider-Strasse 11, D-97080 Wu ¨rzburg, Germany;
2Medizinische Klinik und Poliklinik II der
Universita ¨t Wu ¨rzburg, Oberdu ¨rrbacher Strasse 6, D-97080 Wu ¨rzburg, Germany;
3Oncology Research, Novartis Institutes for Biomedical Research,
Novartis Pharma AG, CH-4057 Basel, Switzerland
BACKGROUND: Heat-shock protein 90 (Hsp90) has a crucial role in both the stabilisation and regulation of various proteins, including
those related to radioresistance. Inhibition of Hsp90 may therefore provide a strategy for enhancing the radiosensitivity of tumour
cells. This study explores the responses of four tumour cell lines (A549, GaMG, HT 1080 and SNB19) to combined treatment with
ionising radiation (IR) and two novel inhibitors of Hsp90, NVP-AUY922 and NVP-BEP800. The techniques used included cell and
colony counts, expression of Hsp90, Hsp70, Akt, survivin, cleaved caspase 3, p53, cell-cycle progression and associated proteins.
DNA damage was analysed by histone gH2AX and Comet assays.
RESULTS: We found that NVP-AUY922 and NVP-BEP800 enhanced radiosensitivity in all tested cell lines. In contrast, only two cell lines
(HT 1080 and GaMG) exhibited an increased rate of apoptosis after drug pretreatment, as revealed by western blot. In all tested cell
lines, the expression of histone gH2AX, a marker of DNA double-strand breaks, after combined drug-IR treatment was higher and its
decay rate was slower than those after each single treatment modality. Drug-IR treatment also resulted in impaired cell-cycle
progression, as indicated by S-phase depletion and G2/M arrest. In addition, the cell cycle-associated proteins, Cdk1 and Cdk4, were
downregulated after Hsp90 inhibition.
INTERPRETATION: These findings show that the novel inhibitors of Hsp90 can radiosensitise tumour cell lines of different entities
through destabilisation and depletion of several Hsp90 client proteins, thus causing the depletion of S phase and G2/M arrest,
increased DNA damage and repair protraction and, to some extent, apoptosis. The results might have important implications for the
radiotherapy of solid tumours.
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Heat-shock proteins 90 (Hsp90s) are ubiquitously and abundantly
expressed polypeptides required for the energy-driven stabilisa-
tion, conformation and function of a large number of cellular
proteins, termed Hsp90 clients (Picard, 2002; Whitesell and
Lindquist, 2005). Several key Hsp90 clients are involved in the
processes characteristic to the malignant phenotype, such as
invasion, angiogenesis and metastasis (Neckers, 2002). Hsp90
clients also contribute to the pathways leading to the induction of
mitogen-activated protein kinases (MAPK) and nuclear factor-
kappa B (NF-kB) (Sato et al, 2003; Mitsiades et al, 2006; Chatterjee
et al, 2007). Moreover, Hsp90 stabilises Raf-1, Akt and ErbB2
proteins (Schulte et al, 1995; Sato et al, 2000; Bull et al, 2004),
which are known to be associated with protection against
radiation-induced cell death (Pirollo et al, 1997; Gupta et al,
2001; Tanno et al, 2004).
The diverse molecular functions of Hsp90 suggest that its
inhibitors could provide a promising strategy for implementing a
multitarget approach to radiosensitisation. Indeed, a number of
studies have already explored Hsp90 as a potential molecular
target for radiosensitisation of tumour cells (Bisht et al, 2003;
Machida et al, 2003; Russell et al, 2003; Bull et al, 2004; Harashima
et al, 2005; Dote et al, 2006; Kabakov et al, 2008; Wu et al, 2009).
Thus, the inhibitor of Hsp90, geldanamycin, and its derivatives
significantly enhance the radiosensitivity of tumour cell lines
derived from a variety of histologies, including glioma, prostate,
pancreas and cervix (Bisht et al, 2003; Enmon et al, 2003; Machida
et al, 2003; Russell et al, 2003; Bull et al, 2004; Harashima et al,
2005; Dote et al, 2006). However, geldanamycins have several
limitations, including poor solubility, formulation difficulties,
hepatotoxicity and extensive metabolism by polymorphic
enzymes, along with drug efflux by P-glycoprotein (Kelland et al,
1999; Eiseman et al, 2005; Brough et al, 2008; Eccles et al, 2008).
Therefore, there has been considerable effort to design small
synthetic inhibitors of Hsp90 with improved bioavailability and
lower toxicity. Both requirements are met by a series of pyrazole
resorcinol compounds that have proven to be stronger inhibitors Revised 3 March 2010; accepted 12 April 2010
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sof Hsp90 than geldanamycin derivatives. Currently, the isoxazole
resorcinol NVP-AUY922 shows the highest affinity for the
NH2-terminal nucleotide-binding site of Hsp90 (Brough et al,
2008; Eccles et al, 2008; Gao et al, 2010), whereas NVP-BEP800
represents a novel fully synthetic, orally available 2-amino-
thieno[2,3-d]pyrimidine class Hsp90 inhibitor (Brough et al,
2009; Stu ¨hmer et al, 2009; Massey et al, 2010). Both compounds
have good pharmaceutical and pharmacological properties. They
also exhibit strong anti-proliferative activity against various
tumour cell lines and primary tumours in vitro and in vivo at
well-tolerated doses (Eccles et al, 2008; Jensen et al, 2008; Stu ¨hmer
et al, 2009; Massey et al, 2010).
This study explores the cytotoxicity and radiosensitising ability
of NVP-AUY922 and NVP-BEP800 in four established cell lines
originated from different tumour entities, including lung carcino-
ma A549, fibrosarcoma HT 1080, and two glioblastoma, SNB19 and
GaMG, cell lines. Each tumour cell line was treated with drug,
ionising radiation (IR) or combined drug-IR exposure. Treated
cells were then analysed for proliferation rate, colony-forming
ability, cell-cycle distribution and expression of several marker
proteins (Hsp90, Hsp70, Akt, phospho-Akt, survivin, p53, cleaved
caspase 3, Cdk1, Cdk2, Cdk4, pRb and so on). In addition,
radiation-induced DNA damage and repair were assessed by
histone gH2AX and Comet assay.
MATERIALS AND METHODS
Cells
The group of human tumour cell lines examined includes lung
carcinoma A549 (p53wt), fibrosarcoma HT 1080 (p53wt) and
two glioblastomas, namely, GaMG (p53mt) and SNB19 (p53mt).
Cells were obtained from the American Type Culture Collection
(Manassas, VA, USA) and routinely cultured under standard
conditions (5% CO2,3 7 1C) in complete growth medium (CGM),
which was either MEM (GaMG, SNB19) or DMEM (A549, HT
1080), supplemented with 10% foetal bovine serum.
Drug treatment
NVP-AUY922 (Brough et al, 2008) and NVP-BEP800 (Brough et al,
2009) were kindly provided by Novartis Institutes for Biomedical
Research (Basel, Switzerland). 17-Dimethylaminoethylamino-
17-demethoxygeldanamycin (17-DMAG) was purchased from
Sigma (Taufkirchen, Germany, D-5193). Drugs were freshly diluted
from frozen aliquots in DMSO stored at  201C. Exponentially
growing cell cultures were incubated with different concentrations
of NVP-AUY922, NVP-BEP800 or 17-DMAG, added to CGM for
24h. Thereafter, CGM was aspirated, and the cell monolayers were
rinsed with PBS, which was then replaced by fresh drug-free CGM.
Control cells were treated in parallel with respective concentrations
of DMSO as a vehicle control.
Growth inhibition assay
The growth inhibition assay was carried out essentially as
described elsewhere (Robles et al, 2006). Serial dilutions of
Hsp90 inhibitors (0–5mM) in CGM were added to cell cultures
in duplicates. The cytotoxicity of each drug was determined
24h later (Robles et al, 2006) using the Cell Titer 96 Aqueous
One Solution Cell Proliferation Assay (Promega, Madison, WI,
USA) according to the manufacturer’s instructions. Control
samples contained the respective concentrations of DMSO.
Duplicate data from two independent experiments were averaged
and normalised against non-treated controls to generate
dose–response curves.
Antibodies
The primary and secondary antibodies used are specified in
Supplementary Information.
X-ray irradiation
Irradiation was performed at room temperature using a 6MV
Siemens linear accelerator (Siemens, Concord, CA, USA) at a dose
rate of 2Gymin
 1. After irradiation, cells were recovered in CGM
for the indicated time until harvest.
Colony survival
Cell survival curves were generated by a standard colony formation
assay as previously described (Djuzenova et al, 2004). Sub-
confluent monolayers of non-treated and drug-treated cells were
irradiated in culture flasks filled with CGM at room temperature by
graded single doses (0–8Gy), seeded in Petri dishes and then
cultivated in CGM for the next 2 weeks. Four replications were
carried out for each exposure point, and the experiments were
repeated at least twice. After 2 weeks, the cells were fixed and
stained with crystal violet (0.6%). Colonies of at least 50 cells were
scored as survivors. The mean survival data for each individual
cell line were fitted to the linear quadratic (LQ) model:
SF ¼ expð aX   bX2Þð 1Þ
where, SF is the survival fraction, X is the irradiation dose and
a and b are the fitted parameters.
Western blot
For immunoblot analysis, whole-cell lysates were prepared
according to standard procedures. Samples equivalent to
10–100mg of protein were separated using 4–12% or 3–8% SDS–
polyacrylamide precast gels (Invitrogen, Karlsruhe, Germany) and
transferred to nitrocellulose membranes according to the manu-
facturer’s prescriptions. For protein detection, membranes were
incubated with respective primary and species-specific peroxidase-
labelled secondary antibodies according to standard protocols. The
levels of protein expression were quantified using Kodak 1D Image
analysing software (Scientific Imaging Systems, Eastman Kodak
Company, Rochester, NY, USA) and normalised to the b-actin
levels.
Comet assay
Comet assay was performed under alkaline conditions following
the protocol reported elsewhere (Djuzenova et al, 2006). Just
before irradiation, drug-treated and control cells were embedded
in a thin layer of agarose spread on glass microscope slides. The
slides were placed on ice, subjected to irradiation and transferred
immediately either into ice-cold lysis buffer or to CGM for the
indicated times. DNA fragmentation was quantified from the ‘Tail
Moment’ (TM, given in arbitrary units, a.u.) defined as the product
of the percentage of DNA in the comet tail and the tail length
(Olive et al, 1990).
Immunocytochemical detection of histone cH2AX and
cell-cycle measurements by flow cytometry
Non-treated and drug-treated cell cultures were irradiated as
subconfluent monolayers in CGM at room temperature. The cells
were then incubated in the same medium under standard
conditions and analysed by flow cytometry 30min, 1 and 2 days
after IR exposure. For analysis, cells were trypsinised, washed
twice in PBS, fixed and stained for gH2AX, according to a protocol
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sdescribed elsewhere (Muslimovic et al, 2008). The cells were then
counterstained with propidium iodide (Sigma P-4170, 10mgml
 1)
in the presence of ribonuclease A (Sigma R-5250, 25mgml
 1)a s
described elsewhere (Djuzenova et al, 1994).
At least 15000 cells were assayed for either histone gH2AX or
DNA distribution using a flow cytometer FACSCalibur (Becton
Dickinson, San Jose, CA, USA) equipped with a 15mW argon-ion
laser. Cellular green (histone gH2AX) or red fluorescence (staining
with propidium iodide) was acquired in logarithmic or linear
mode. The output data presented as one-dimensional histograms,
that is, the distributions of histone gH2AX or PI-DNA signals
within cell samples, were analysed using the WinMDI program
obtained from J. Trotter (The Scripps Research Institute, La Jolla,
CA, USA) and the ModFit LT program (Verity Software House,
Topsham, ME, USA).
Statistics
Data are presented as means (±s.d. or ±s.e.). Mean values
were compared by Student’s t-test. The threshold of statistical
significance was set at Po0.05. Statistics and fitting of experi-
mental curves were performed with the program Origin (Microcal,
Northampton, MA, USA).
RESULTS
Effects of Hsp90 inhibitors on cell growth and
radiosensitivity
We first analysed the effects of Hsp90 inhibitors on the growth of
tumour cell lines. To this end, we treated cells for 24h with
different drug concentrations ranging from 0 to 5mM, and then
analysed cell viability by MTT assay. As seen in Figure 1, GaMG
and HT 1080 cell lines were more sensitive to high concentrations
(5mM) of Hsp90 inhibitors than were A549 and SNB19 cells.
Dose–response curves show that, at a concentration of B200nM,
all tested drugs yielded B70% viability in all cell lines. For that
reason, the drugs were used at the same concentration of 200nM in
subsequent experiments. Besides this, the selected drug concen-
tration is consistent with the previously reported 100nM for
17-DMAG (Robles et al, 2006; Koll et al, 2008).
On the basis of the cytotoxicity data shown in Figure 1, drug-
pretreated (200nM, 24h) cells were exposed to an X-ray dose of up
to 8Gy and their radiation sensitivities were analysed by means of
the colony survival test. Figure 2 shows the normalised cell survival
responses (symbols) plotted vs the X-ray dose, along with the best
fits of the LQ model (equation (1)) to the data. Judging by the
correlation coefficients, which range between 0.97 and 0.99, the LQ
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Figure 1 Cytotoxicity assay after exposure of tumour cell lines (A, A549; B, GaMG; C, HT 1080; and D, SNB19) to serial dilutions of NVP-AUY922
(filled circles), NVP-BEP800 (triangles) and 17-DMAG (squares), for 24h. Survival was measured by standard MTT assay. Triplicate data from two
experiments were averaged and normalised against non-treated controls (DMSO) to generate dose–response curves. The numbers of viable cells are
expressed as percentage (mean±s.d.) relative to corresponding controls.
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smodel provides reasonable approximations to the experimental
data. The plating efficiencies of non-irradiated cell lines and the
fitted parameters a and b obtained by non-linear regression of the
LQ model are summarised in Table 1 for each individual cell line.
The table also includes data for the surviving cell fractions at
2Gy (SF2) and the radiation doses (D10) resulting in 10% survival.
Comparison of the SF2 and D10 values of drug-treated cell samples
with the corresponding data of untreated controls (Table 1) reveals
a marked drug-induced reduction of both SF2 and D10 values in
four cell lines. The data shown in Figure 2 and Table 1 prove the
three tested Hsp90 inhibitors (NVP-AUY922, NVP-BEP800 and
17-DMAG) as potent radiosensitisers that significantly enhance
in vitro radiotoxicity, regardless of the p53 status of the particular
tumour line.
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Figure 2 Clonogenic abilities of tumour cell lines (A, A549; B, GaMG; C, HT 1080; and D, SNB19) as functions of radiation dose and drug exposure.
Control (DMSO treated, empty circles) and drug-treated (NVP-AUY922 – filled circles; NVP-BEP800 – triangles; 17-DMAG – squares) cells were irradiated
with single ionising radiation (IR) doses ranging between 1 and 8Gy. After irradiation, cells were plated in CGM and incubated under standard conditions.
After 2 weeks, colonies containing at least 50 cells were scored as survivors. Data derived from at least two independent experiments for each cell line were
pooled together and fitted by a linear quadratic equation (equation (1)). The s.d. values are indicated by error bars.
Table 1 Cloning efficiencies and radiosensitivity parameters
a of in vitro irradiated tumor cell lines untreated and pretreated with the Hsp90 inhibitors
Cell line Plating efficiency SF2 a (Gy
 1) b (Gy
 2)D 10 (Gy)
b Factor (D10 control)/(D10+inh.)
A549 – contr. 0.8±0.1 0.70±0.05 0.1±0.03 0.04±0.01 6 1.0
+AUY922 0.5±0.01 0.33±0.06 0.4±0.2 0.04±0.05 4 1.5
+BEP800 0.8±0.1 0.52±0.1 0.2±0.1 0.04±0.01 5 1.2
+17DMAG 0.7±0.1 0.41±0.08 0.3±0.2 0.07±0.05 4 1.5
GaMG – contr. 0.3±0.1 0.84±0.01 0.01±0.01 0.04±0 8 1.0
+AUY922 0.1±0 0.46±0.04 0.1±0.07 0.1±0 4 1.8
+BEP800 0.3±0.1 0.57±0.08 0.1±0.1 0.07±0.01 5 1.4
+17DMAG 0.1±0.05 0.44±0.02 0.1±0 0.1±0 4 1.8
HT1080 – contr. 0.1±0.04 0.81±0 — 0.05±0 7 1.0
+AUY922 0.02±0.03 0.63±0.2 0.1±0.2 0.06±0.01 5 1.4
+BEP800 0.1±0.03 0.59±0.2 0.06±0.08 0.08±0.03 5 1.4
+17DMAG 0.03±0.01 0.70±0.1 — 0.1±0.02 5 1.4
SNB19 – contr. 0.3±0.1 0.53±0.3 0.3±0.4 0.03±0.04 6 1.0
+AUY922 0.2±0.1 0.40±0.3 0.4±0.4 0.07±0.04 5 1.3
+BEP800 0.2±0.1 0.45±0.2 0.3±0.2 0.06±0.01 5 1.3
+17DMAG 0.1±0.1 0.53±0.2 0.1±0.1 0.1±0 4 1.3
Abbreviations: contr.¼control; inh.¼inhibitor.
aMean (±s.d.) from at least two independent experiments.
bD10 is the radiation dose required to reduce clonogenic survival
by 10%.
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sEffects of Hsp90 inhibition and/or radiation on multiple
signalling pathways
To elucidate the molecularmechanisms of radiosensitisation (Figure 2)
caused by the Hsp90 inhibitors, we further examined the expression of
several proteins by western blotting (Figure 3 and Supplementary
Figure S1). Figure 3 shows exemplarily western blot data of control
and drug-treated HT 1080 cells probed for Hsp90, Hsp70, Akt, p53,
survivin, cleaved caspase 3, Raf-1 and phospho-Akt 30min after
irradiation. As evident from the figure, the expression levels of Hsp90
and Hsp70 proteins in HT 1080 cells after drug treatment alone or in
combination with IR were much higher than that in control (DMSO
treated). Expression of the anti-apoptotic protein Akt in irradiated
drug-treated cells was somewhat lower than those in the correspond-
i n gn o n - t r e a t e ds a m p l e ,w h i c hm a yb ea ni n d i c a t i o no fi n c r e a s e d
apoptosis. The reduction of Akt, however, did not reach statistical
significance in the case of HT 1080 cells, whereas in the other tested
cell lines, the level of Akt decreased significantly (Supplementary
Figure S1). Similarly, Hsp90 inhibitors alone or in combination with
radiation significantly suppressed the prosurvival protein Raf-1. Note
that both proteins, Akt and Raf-1, are clients of Hsp90. The expression
of survivin, a further anti-apoptotic and Hsp90 client protein, in drug-
treated cells was higher than those in control samples.
As expected, the expression of p53, a client protein of Hsp90,
varied markedly among the four tested cell lines, two of which
(A549 and HT 1080) were wild type for p53, whereas GaMG and
SNB19 were p53-mutated cells. Thus, control (i.e., DMSO treated)
HT 1080 cells exhibited very low or no expression of p53, which
is typical for p53wt cells. However, after treatment with
NVP-AUY922 and 17-DMAG, and to a lesser extent in the case
of NVP-BEP800, HT 1080 cells revealed detectable amounts of
p53. Qualitatively similar results for the expression of Hsp90/70,
p53 and survivin were obtained 24h after irradiation (data not
shown), whereas the expression of Akt was mostly recovered after
treatment with all substances. At the same time, the Raf-1 protein
reached a near normal level only in the case of NVP-BEP800
(data not shown).
Another effect of the Hsp90 inhibitors is an increased expression
of cleaved caspase 3 in HT 1080 (Figure 3) and GaMG
(Supplementary Figure S1B) cells pretreated with all tested drugs.
Accordingly, the expression of phospho-Akt (Figure 3) decreased.
Two other tested cell lines, A549 and SNB19, did not show any
detectable changes in cleaved caspase 3 (data not shown).
To summarise, our western blot data on apoptosis-associated
proteins (Figure 3 and Supplementary Figure S1) can explain the
strong radiosensitising effects (Figure 2) of NVP-AUY922 and
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Hsp90 (90 kDa)
Hsp70 (70 kDa)
0.9 1.7 1.2 1.6 0.8 1.5 1.3 1.5 Hsp90/actin
0.9 1.8 1.3 1.7 0.8 1.5 1.4 1.6 Hsp70/actin
Akt (56 kDa)
0.7 0.6 0.5 0.6 0.7 0.6 0.6 0.5 Akt/actin
p53 (53 kDa)
0.1 0.3 0.2 0.3 0.1 0.3 0.2 0.3 p53/actin
Survivin (19 kDa)
0.2 0.9 0.8 0.8 0.2 1.0 0.8 1.1 Survivin/actin
Phospho-Akt (60 kDa)
0.3 0.1 0.1 0.1 0.4 0.2 0.2 0.1
0.1 0 0 0 0.3 0 0 0 Phospho-Akt/actin
Cleaved caspase 3 (19 and 17 kDa)
0.2 0.4 0.4 0.5 0.3 0.5 0.4 0.3 19 kDa cleaved caspase 3/actin
0.2 0.8 0.5 0.7 0.3 0.7 0.3 0.7 17 kDa cleaved caspase 3/actin
Raf-1 (73 kDa)
0.6 0.1 0.1 0.1 1.7 0.2 0.3 0.2 Raf-1/actin
Figure 3 Western blot analysis of expression levels and migration patterns of Hsp90, Hsp70, survivin, Akt, p53, survivin, cleaved caspase 3, phospho-Akt
and Raf-1 proteins in DMSO-treated, drug-treated and/or irradiated (8Gy, 30min after irradiation) HT 1080 cells. Each protein band was normalised to the
intensity of b-actin used as loading control, and the ratios are given by the numbers.
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sNVP-BEP800 in only two (HT 1080 and GaMG) out of four tested
cell lines. Further support for the involvement of apoptosis in
radiosensitising drug activity came from the measurements of cells
with hypodiploid nuclei and cellular debris as indications of late-
onset apoptosis, in log-scaled histograms in cell samples including
both floating and adherently growing cells (Supplementary Figure
S2 and Supplementary Table S1). Using this approach (Djuzenova
and Flentje, 2002), we found increased fractions of cells with
hypodiploid DNA content and cellular debris in three cell lines
(except A549) pretreated with NVP-AUY922 and 17-DMAG (24h
after irradiation). The effect of NVP-BEP800 was less pronounced
and seen only 48h after irradiation.
In apparent contrast to the above considerations on the role
of apoptosis, both NVP-AUY922 and NVP-BEP800 increased
the expression of the anti-apoptotic protein survivin in
irradiated HT 1080 and GaMG cells (Figure 3 and Supplementary
Figure S1). This finding points towards the possibility that
Hsp90 inhibition can improve the survival of a particular cell
line, for instance, by conferring radioresistance on tumour
cells through survivin induction. Hence, at least in the case of
HT 1080 and GaMG cells, Hsp90 inhibitors seemed to simul-
taneously induce opposite, pro- and anti-apoptotic effects in
irradiated tumour cells.
DNA fragmentation caused by inhibitors of Hsp90 and
radiation
To elucidate the radiosensitising effects of Hsp90 inhibitors on
their colony-forming ability (Figure 2), we evaluated DNA
fragmentation in control and drug-treated cells after irradiation
by means of the alkaline Comet assay. The extent of DNA
fragmentation was assessed from the comet TMs measured
immediately (TM0) and up to 30min after irradiation with
8Gy (Figure 4).
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Figure 4 DNA damage induction and repair profiles measured by the alkaline Comet assay in human tumour cell lines (A–C, A549; D–F, GaMG; G–I,
HT 1080; and J–L, SNB19) pretreated with drugs (200nM, 24h) and irradiated with 8Gy of X-rays in vitro. The extent of DNA damage was measured
quantitatively by the comet Tail Moment (TM). Each point (bar) represents the mean value (±s.d.) of TM data measured in about 150 cells from two
independent experiments and normalised against untreated controls (circles, dashed line). The curves are best least-square fits of a monoexponential
function to the experimental data points. Numbers indicate the repair half-time constants (min) for each curve/treatment and the ratios of the repair half-
time constants of drug-pretreated cells to control cells.
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sContrary to expectations, the three tested Hsp90 inhibitors
significantly decreased the initial TM0 values in all cell lines
studied here. Irrespective of the drug used, the initial TM0 values
in irradiated drug-treated cells (in relation to DMSO-treated cells)
reduced in the following order: A5494HT 10804GaMGESNB19.
Despite the lower initial fragmentation, the restoration of DNA
damage after irradiation occurred more slowly in cells pretreated
with Hsp90 inhibitors. This is evident from the increased t1/2
values given in Figure 4. The exception was the HT1080 cell line,
in which the t1/2 values were almost unaffected by the drugs.
Taken together, the data obtained by western blot (Figure 3 and
Supplementary Figure S1), sub-G1 DNA measurements (Supple-
mentary Figure S2 and Supplementary Table S1) and Comet assay
(Figure 4) revealed multiple effects of Hsp90 inhibitors on tumour
cells at the molecular level. Most of the effects analysed so far,
however, do not account for or even disagree with the strong
radiosensitising activity of these drugs revealed by the colony-
forming assay (Figure 2) in all tested tumour lines. To move
forward with the elucidation of the controversial data, we further
analysed the impact of Hsp90 inhibitors on the induction of
histone gH2AX, a marker of DNA double-strand breaks (DSBs) in
irradiated tumour cells.
Effects of Hsp90 inhibitors and IR on the induction and
decay of histone cH2AX
The induction of DNA DSBs, as analysed by the expression of
phosphorylated histone H2AX (Rogakou et al, 1998), was
measured 30min (Figure 5), and 24 and 48h (Figure 6) after
irradiation of tumour cells, non-treated or pretreated with Hsp90
inhibitors. As evident from the flow cytograms of DMSO-treated
control cultures (Figure 5, upper row, light grey histograms), the
background expression of histone gH2AX differed markedly
among the four tested cell lines. HT 1080 cells exhibited the
lowest background level of gH2AX with the mean fluorescence
intensity of B46a.u. In A549, SNB19 and GaMG cells, the amounts
of endogenous histone gH2AX were about 62, 64 and 78a.u.,
respectively. At 30min after IR, the expression of histone gH2AX
in control cells increased by a factor of 2–4 (Figure 5, upper row,
black histograms).
In the majority (except A549) of cell lines tested, Hsp90
inhibitors induced dramatic cell type-specific changes in gH2AX
expression (Figure 5, rows 2–4, light grey histograms), compared
with DMSO-treated controls (Figure 5, upper row, light grey
histograms). The gH2AX histograms of drug-treated cells were
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smostly bimodal and spread over 2–3 decades of fluorescence
intensity. This finding implies that each cell line consists of two
distinct sub-populations differing strongly in their sensitivity to
Hsp90 inhibitors.
Combined drug-IR treatment (Figure 5, rows 2–4, black
histograms) strongly increased gH2AX expression, compared with
each treatment modality alone. In three out of four cell lines,
combined treatment produced very narrow and mostly unimodal
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Figure 5 Typical distributions of nuclear histone gH2AX in four tumour cell lines detected 30min after irradiation with 8Gy, and after a combined drug-
ionising radiation (IR) treatment. Cells were stained with anti-histone gH2AX and analysed by flow cytometry using logarithmic amplification mode. Numbers
denote the mean histone gH2AX expression for the respective cell sub-population and the percentage of cells in the sub-population. Black and light grey
histograms represent irradiated and non-irradiated cells, respectively. To facilitate visual comparison, the modal gH2AX values in the DMSO-treated and
irradiated sample are indicated by dashed vertical lines.
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sdistributions of histone gH2AX, which contrasted with those
induced by drugs alone (Figure 5, rows 2–4, light grey histograms).
The exception was the lung carcinoma line (A549), in which the
combined drug-IR treatment caused a bimodal expression pattern
of gH2AX (Figure 5, left-hand column, black histograms), similar to
that caused by drug treatment alone. Besides this, the amounts of
DNA DSBs in A549 cells after combined drug-IR treatment
increased only moderately (by about 20%) above the corresponding
data of irradiated cell samples without Hsp90 inhibitors.
In all tested cell lines, increasing the repair time from 30min to
24 and 48h after IR alone resulted in a near-complete restoration
of the expression of histone gH2AX to the background level
(Figure 6, only data for GaMG cells are shown). Drug-treated and
then irradiated cells, however, still exhibited elevated amounts of
histone gH2AX 24h after irradiation (Figure 6, upper row, light
grey histograms). At 48h after irradiation, the amounts of residual
histone gH2AX further decreased, but the values were still higher
(Figure 6, bottom row, black histograms) than those in the
corresponding control sample (Figure 6, bottom row, left-hand
light grey histogram). Qualitatively similar data were obtained for
the other three tested cell lines (averaged data from three
independent experiments with four cell lines are shown in
Supplementary Figure S3).
Effects of Hsp90 inhibitors and IR on cell-cycle
progression
Further efforts to identify the mechanisms underlying the radio-
sensitising effect of Hsp90 inhibitors were focused on their
possible impact on cell-cycle progression. Cells were treated with
200nM of drugs for 24h and analysed by flow cytometry for the cell
cycle-phase distribution. As seen from Supplementary Table S2,
Hsp90 inhibitors caused a depletion of the S phase and an
accumulation of cells with G2/M DNA content. Drug-treated cells
were then transferred into drug-free medium, irradiated with 8Gy,
cultured for the next 24 and 48h and then analysed once again for
cell-cycle distribution. Because of space limitation, representative
cell-cycle data are provided only for A549 cells (Figure 7), whereas
histograms for the other three cell lines are shown in Supple-
mentary Figure S4. Supplementary Table S3 summarises cell-cycle
data from three independent experiments for all cell lines tested.
The large portions of cells in S and G2/M phases in the untreated
control sample (Figure 7, top row, left-hand histogram) prove that,
at the beginning of these experiments, the cell culture was in the
exponential growth phase.
In non-irradiated samples (first and third columns in Figure 7),
NVP-AUY922 and 17-DMAG induced a marked long-term increase
in the G2/M peak, lasting for at least 48h after drug removal. Both
drugs also caused a strong depletion of the S phase during the first
24h, followed by partial recovery during the subsequent incuba-
tion for up to 48h in drug-free medium (Figure 7, third column).
In this particular cell line, treatment with NVP-BEP800 alone
caused comparatively small changes (G2/G1¼0.4) in cell-cycle
distribution, which were partly recovered 48h after incubation in
drug-free medium (G2/G1¼0.2).
As expected, radiation alone caused a significant increase in
G2/M cells (Figure 7, top row, second and fourth histograms from
the left). In the case of NVP-AUY922 and 17-DMAG, combined
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Figure 6 Representative distributions of nuclear histone gH2AX in the GaMG tumour cell line detected 24 (upper row) and 48h (bottom row) after
irradiation with 8Gy or after a combined drug-ionising radiation (IR) treatment. Black and light grey histograms represent irradiated and non-irradiated cells,
respectively. The modal gH2AX value in the control (DMSO treated) non-irradiated sample is indicated by a dashed vertical line. For details, see legend
to Figure 5.
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Figure 7 Effects of Hsp90 inhibitors, ionising radiation (IR) and combined drug-IR treatment on the cell cycle-phase distribution in the A549 cell line. Cells
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sdrug-IR treatment did not cause any additional changes in
cell-cycle distribution, compared with drug treatment alone.
In sharp contrast, combined NVP-BEP800-IR treatment (Figure 7,
third row) resulted in a much stronger cell-cycle disturbance than
each agent alone.
Effects of Hsp90 inhibitors on the expression of cell
cycle-related proteins
The observed alterations in the cell cycle caused by Hsp90
inhibitors prompted us to analyse the expression levels of various
cell cycle-regulating factors, such as cyclin-dependent kinases
(Cdk1, Cdk2, Cdk4) and pRb, by western blotting. As shown in
Figure 8 and Supplementary Figure S5, Hsp90 inhibitors reduced
the levels of Cdk1 in all tested cell lines, although to different
extents. Similarly, the levels of Cdk4 decreased significantly in case
of NVP-AUY922 and 17-DMAG, and to a lesser extent in the case
of NVP-BEP800. The expression of phosphorylated Rb decreased
strongly in two (A549 and HT 1080) out of four tested cell lines
after Hsp90 inhibition with all tested substances. Another finding
was that Cdk2, a close relative of the Hsp90-dependent Cdk4
kinase, was unaffected by drug treatment.
DISCUSSION
Previous studies have shown that inhibition of Hsp90 enhances the
radiation response of several cell lines derived from a variety of
human tumour entities (Bisht et al, 2003; Enmon et al, 2003;
Machida et al, 2003; Russell et al, 2003; Bull et al, 2004; Harashima
et al, 2005; Dote et al, 2006). These findings validate the molecular
chaperone Hsp90 as a clinically relevant target for tumour
radiosensitisation. The molecular mechanisms underlying the
interaction between IR and conventional Hsp90 inhibitors, such
as the geldanamycin derivatives 17-AAG and 17-DMAG, have not
yet been clearly identified. One of the proposed mechanisms to
explain the radiosensitising effects of geldanamycins involves the
selective degradation of several key proteins responsible for
radioresistance, including ErbB2, EGFR, Raf-1 and Akt (for review,
see Chinnaiyan et al, 2006). However, the degradation of ErbB2
induced either by 17-DMAG (Bull et al, 2004; Dote et al, 2005) or
by siRNA (Dote et al, 2005) does not enhance the radiosensitivity
of various carcinoma cell lines. These findings suggest the
involvement of other mechanisms in the radiosensitising activity
of Hsp90 inhibitors. Besides this, geldanamycin and its derivatives
have several limitations for clinical use (see the Introduction
section, Kelland et al, 1999; Eiseman et al, 2005; Eccles et al, 2008).
In contrast to geldanamycin derivatives, the isoxazole resorcinol
Hsp90 inhibitor NVP-AUY922 has recently shown promising
results with regard to its pharmaceutical and pharmacological
properties, in conjunction with a well-tolerable toxicity against
different tumour cell types in vitro and in vivo (Eccles et al, 2008;
Jensen et al, 2008). Compared with NVP-AUY922, the novel,
structurally distinct Hsp90 inhibitor NVP-BEP800 tested here has
an improved oral bioavailability (Brough et al, 2009; Massey et al,
2010). In this study, we systematically applied a multitarget
approach to explore the impact of NVP-AUY922 and NVP-BEP800
on the radiation response of tumour cells.
Our colony survival experiments identified NVP-AUY922 and
NVP-BEP800 as potent radiosensitisers in all tumour cell lines
studied here (Figure 2). However, only two (HT 1080 and GaMG)
out of four tested tumour cell lines exhibited, after treatment with
NVP-AUY922 (but not with NVP-BEP800), a distinct expression of
cleaved caspase 3, as revealed by western blot analysis (Figure 3
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Figure 8 Effects of Hsp90 inhibitors on the expression of cell-cycle regulatory proteins in the SNB19 tumour cell line. Total cell extracts were prepared
30min after irradiation with 8Gy, resolved by SDS–PAGE, blotted and immunostained according to standard procedures. Each protein band was
normalised to the intensity of b-actin used as loading control, and the ratios are denoted by the numbers.
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sand Supplementary Figure S1). At the same time, the levels of
Raf-1, and to a lesser extent of Akt, were reduced by the Hsp90
inhibitors in all tested cell lines. The two proteins (cleaved caspase
3 and Raf-1) are of particular interest because their inhibition has
been associated with enhanced radiation sensitivity in some
systems (Gupta et al, 2001; Shintani et al, 2006). The role of
apoptosis in the radiosensitisation with the novel Hsp90 inhibitors
was further supported by the increased percentage of cells with
hypodiploid DNA contents and debris (Supplementary Figure S2).
This approach revealed the late onset of apoptosis in most cell
lines (except A549) pretreated with NVP-AUY922 and 17-DMAG,
and to a much lesser extent after treatment with NVP-BEP800
(Supplementary Table S1 and Supplementary Figure S2). Conse-
quently, the radiosensitising activities of NVP-AUY922 and
NVP-BEP800 in all tested cell lines cannot be explained solely by
the drug-mediated susceptibility to apoptosis.
Functional tumour suppressor protein p53 was apparently
not essential for the radiosensitising action of NVP-AUY922 and
NVP-BEP800, because both drugs radiosensitised all tested cell
lines, independent of their p53 status (Figures 2 and 3). This
finding is consistent with the recent data for two non-small-cell
lung cancer cell lines, NCI-H460 and A549 (Koll et al, 2008), but it
conflicts with the results for squamous carcinoma cell lines
(Shintani et al, 2006), indicating that the Hsp90 inhibitor 17-AAG
is a more efficient radiosensitiser in a cell line with p53 wild type
compared with four p53-mutated cell lines.
Summarising the western blot data shown in Figure 3, neither
changes in survival markers (Hsp90, Hsp70, Akt, phospho-Akt,
Raf-1 and survivin) and apoptosis-associated protein (cleaved
caspase 3) nor alterations in p53 were significant to account for the
sensitivity of two (A549 and SNB19) out of four tested cell lines to
NVP-AUY922 and NVP-BEP800, either as a drug treatment alone
or in combination with radiation.
At variance with expectations, the alkaline Comet assay revealed,
in all tested cell lines, a decrease in TM values and thus a lower
DNA fragmentation after combined drug-IR treatment, compared
with those induced by IR alone (Figure 4). The minor DNA
fragmentation can be explained by the remarkable changes in the
cell cycle caused by Hsp90 inhibitors, that is, an S-phase depletion
and G2/M arrest (Figure 7), which were apparently associated with
large alterations in DNA compactness. As shown elsewhere (Olive
and Bana ´th, 1993), cells in the S phase show the highest TM values,
whereas the TM values of G2/M cells are even lower than those in
the G1 phase.
It should be noted that the Comet assay does not provide a
measure for radiosensitivity in the conventional sense, that is,
chromosome breakage, micronucleus formation, reduced growth
and cloning survival, or increased mutation frequency. Rather, the
Comet assay evaluates chromatin integrity as a function of time
immediately after irradiation. Therefore, differences in chromatin
compaction can strongly affect the results of the Comet assay
(Noz et al, 1996). The recognition of DNA damage by the Comet
assay is also well known to rely on a number of factors involved
in the release of DNA from the nuclear protein matrix (Speit and
Hartmann, 1999). In view of the above considerations, the
observed drug-mediated reduction of IR-induced DNA fragmenta-
tion (Figure 4) might have resulted from the drug-mediated, cell
cycle-related changes in the compactness of chromatin/DNA
structure.
Despite the lower initial DNA fragmentation detected by the
Comet assay, the rates of DNA restitution in three cell lines (A549,
GaMG and SNB19) after a combined drug-IR treatment were lower
than those after IR alone. These results strongly suggest the role of
Hsp90 and its clients in the restitution of IR-induced DNA
fragmentation. This conclusion is consistent with recent findings
that combined 17-DMAG/IR treatment inhibits DNA repair in
two human pancreatic cell lines, analysed by a neutral Comet
assay (Dote et al, 2005). Similarly, an alkaline Comet assay has
also revealed an impaired radiation-induced DNA repair in
DMAG-treated lung carcinoma H460 cells (Koll et al, 2008).
Contrary to our data, Koll et al (2008) have also found increased
TM values after irradiation of DMAG-treated cells, compared with
non-treated ones. This discrepancy can be explained by the
differences in the experimental protocols, including cell scraping
in ice-cold PBS, cell lines used and so on.
A further critical determinant of radiation-induced cell death is
the induction and repair of DNA DSBs, which can be probed
very sensitively by histone gH2AX (Rogakou et al, 1998). In this
study, drug-treated tumour cell samples were found to express two
distinct sub-populations (responding and non-responding to
drug) differing markedly in their gH2AX contents (Figure 5)
spreading over 2–3 decades of intensity, as well as in the
percentage of cells in each sub-population. Given that all cell lines
used here had similar cell-cycle distributions before drug
treatment, the gH2AX expression mediated by the drugs alone
(without IR) was more cell-line specific rather than coupled with
the cell cycle.
Combined drug-IR treatment induced higher amounts of
DNA DSBs measured by histone gH2AX than each treatment
alone (Figure 5). Moreover, the repair of DNA DSBs induced
by combined treatment occurred much more slowly than after
irradiation alone (Figure 6 and Supplementary Figure S3). These
data are in accordance with the delayed dispersal of histone
gH2AX in the MiaPaCa pancreas carcinoma cell line, which
received the combined 17DMAG/radiation treatment (Dote et al,
2006). The authors suggest that 17DMAG inhibits the repair of
DNA DSBs induced by radiation (Dote et al, 2006), Similarly, an
inhibition of homologous DNA recombination repair, that is,
degradation of BRCA2 and alteration of Rad51 by 17-AAG, causes
the radiosensitisation of prostate carcinoma DU145 and lung
squamous carcinoma SQ-5 cell lines (Noguchi et al, 2006). Similar
effects on histone gH2AX, for example, prolonged persistence of
DNA damage measured by this sensitive marker, have been shown
in several studies using HDAC inhibitors that indirectly block
Hsp90 by acetylation (Zhang et al, 2007; Zuco et al, 2010). As
suggested by a reviewer, we analysed the expression of several
DNA repair proteins, including Ku70, Ku80, Rad50, Rad51,
DNA-PKcs and BRCA2. We found that all drug-treated cells were
depleted of Ku70/80 proteins (data not shown), whereas other
proteins were not significantly affected by drug treatment. Further
studies will be needed to clarify the mechanisms of DNA repair
distortion, which will be a subject of future research in our
laboratory.
Finally, all tested Hsp90 inhibitors caused a substantial G2/M
block that was even more pronounced after subsequent irradiation
in case of NVP-BEP800-treated cells. In addition, NVP-AUY922
induced a temporary depletion of S-phase cells. These data are in
agreement with the ability of 17-DMAG and NVP-AUY922 to cause
a loss of S phase and an accumulation of cells with G2/M DNA
content (Eccles et al, 2008; Koll et al, 2008). The effects of Hsp90
inhibitors on the cell cycle reported here and elsewhere (Eccles
et al, 2008; Koll et al, 2008) are, however, quite contrary to the
findings that 17-DMAG abrogates the radiation-induced arrest of
three human tumour cell lines in the S and G2 phases (Bull et al,
2004). Similarly, geldanamycin has also been found to abolish
G2-phase arrest in human colon adenocarcinoma cells that are null
or mutant for p53 (Moran et al, 2008).
To explain remarkable cell-cycle changes in response to Hsp90
inhibitors, we analysed the expression levels of several cell
cycle-dependent proteins. It is worth mentioning that important
proteins related to the cell cycle, including Cdk1, Cdk2, Cdk4 and
p53 (Figure 8), are well-known clients of Hsp90 (Picard, 2002). We
found that Hsp90 inhibition led to downregulation of Cdk4 in all
tested cell lines. However, only two cell lines, A549 and HT 1080
(both wt p53), exhibited hypophosphorylation of Rb, which
functions as a blocker of cell-cycle progression at the G1/S
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scheckpoint (Stewart et al, 2003). Another finding is that Hsp90
inhibitors markedly reduced Cdk1 levels in HT 1080, GaMG and
SNB19, and to a lesser extent in A549 cells, thus causing a G2/M
arrest that is independent of the cellular p53 status. Checkpoint
protein Cdk1 has been identified as an Hsp90 client and is a key
transducer of G2/M-phase arrest in response to the drug treatment.
To sum up, our data demonstrate enhanced radiosensitivity in
four solid tumour cell lines pretreated with NVP-AUY922 or
NVP-BEP800. The complex mechanisms underlying the radio-
sensitisation by these novel Hsp90 inhibitors involve apparently
multiple, cell-line-specific pathways that lead to the destabilisation
and degradation of several Hsp90 client proteins, thus causing a
dramatic cell-cycle impairment that leads to a slower proliferation
of tumour cells, increased DNA damage and protraction of DNA
repair after irradiation, and to a lesser extent, to apoptosis. The
data are of particular interest for the radiation therapy of cancer,
because NVP-AUY922 is currently in clinical trials Phase I–II
(www.clinicaltrials.gov). Besides raising important questions with
regard to the mechanisms of radiosensitisation, the in vitro data
presented here will surely prompt further clinical studies on the
possibility of combining NVP-AUY922 and NVP-BEP800 with
radiation, which may open up a promising approach for improved
local control of cancer.
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